These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21189365)

  • 1. Ondansetron-induced dystonia, hypoglycemia, and seizures in a child.
    Patel A; Mittal S; Manchanda S; Puliyel JM
    Ann Pharmacother; 2011 Jan; 45(1):e7. PubMed ID: 21189365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.
    Lee CY; Ratnapalan S; Thompson M; Nathan PC; Closs J; French A; Punnett A; Garcia-Bournissen F; Ito S; Koren G
    Can J Clin Pharmacol; 2010; 17(1):e1-4. PubMed ID: 20051608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of ondansetron is associated with lethal outcome.
    Gener B; Burns JM; Griffin S; Boyer EW
    Pediatrics; 2010 Jun; 125(6):e1514-7. PubMed ID: 20439600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nausea and vomiting: Therapeutic orphans of pediatric oncology.
    Bernhardt MB
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28561924
    [No Abstract]   [Full Text] [Related]  

  • 6. Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting.
    Rosow CE; Haspel KL; Smith SE; Grecu L; Bittner EA
    Anesth Analg; 2008 May; 106(5):1407-9, table of contents. PubMed ID: 18420852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron and seizures.
    Singh NN; Rai A; Selhorst JB; Acharya JN
    Epilepsia; 2009 Dec; 50(12):2663-6. PubMed ID: 19490041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
    Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
    Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
    Goldsmith B
    Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
    [No Abstract]   [Full Text] [Related]  

  • 10. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
    Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F
    J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
    ; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
    J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron for gastroenteritis in children and adolescents.
    Lalani N; Gaco D
    Am Fam Physician; 2015 Apr; 91(7):Online. PubMed ID: 25884755
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis.
    Neufeld SM; Newburn-Cook CV
    J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haloperidol plus ondansetron versus ondansetron alone for prophylaxis of postoperative nausea and vomiting.
    Grecu L; Bittner EA; Kher J; Smith SE; Rosow CE
    Anesth Analg; 2008 May; 106(5):1410-3, table of contents. PubMed ID: 18420853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Bergemalm J; Ludvigsson JF
    Lakartidningen; 2018 Feb; 115():. PubMed ID: 29406558
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective evaluation of ondansetron for undifferentiated nausea and vomiting in the prehospital setting.
    Warden CR; Moreno R; Daya M
    Prehosp Emerg Care; 2008; 12(1):87-91. PubMed ID: 18189184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
    Abali H; Celik I
    Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
    Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
    Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalised seizures following ondansetron.
    Sharma A; Raina V
    Ann Oncol; 2001 Jan; 12(1):131-2. PubMed ID: 11249042
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral ondansetron for gastroenteritis in a pediatric emergency department.
    Freedman SB; Adler M; Seshadri R; Powell EC
    N Engl J Med; 2006 Apr; 354(16):1698-705. PubMed ID: 16625009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.